Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry

MLA

Spekhorst, Lotte S., et al. “Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-Term Results From the Daily Practice BioDay Registry.” JAMA Dermatology Vol.158 (2022) Nr.9 p.1048-1056 [ISSN 2168-6068], 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1376706998&authtype=sso&custid=ns315887.

APA

Spekhorst, L. S., de Graaf, M., Zuithoff, N. P. A., van den Reek, J. M. P. A., Kamsteeg, M., Boesjes, C. M., Romeijn, G. L. E., Loman, L., Haeck, I., Oosting, A. J., de Boer-Brand, A., Touwslager, W. R. H., Flinterman, A., van Lynden-van Nes, A. M. T., Gostynski, A. H., de Bruin-Weller, M. S., & Schuttelaar, M.-L. (2022). Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry. JAMA Dermatology Vol.158 (2022) Nr.9 p.1048-1056 [ISSN 2168-6068].

Chicago

Spekhorst, Lotte S, Marlies de Graaf, Nicolaas P A Zuithoff, Juul M P A van den Reek, Marijke Kamsteeg, Celeste M Boesjes, Geertruida L E Romeijn, et al. 2022. “Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-Term Results From the Daily Practice BioDay Registry.” JAMA Dermatology Vol.158 (2022) Nr.9 p.1048-1056 [ISSN 2168-6068]. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1376706998&authtype=sso&custid=ns315887.